Lyra Therapeutics Shares Rise on Phase 2 Study Success

Lyra Therapeutics Shares Rise on Phase 2 Study Success

Source: 
Marketwatch
snippet: 

Lyra Therapeutics shares moved higher in premarket trading Tuesday after the clinical-stage biotechnology company reported a successful Phase 2 study of its LYR-220 drug candidate in the inflammatory sinus disease chronic rhinosinusitis.